David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Comcast
CMCSA
|
+$354M |
| 2 |
Wells Fargo
WFC
|
+$274M |
| 3 |
IBM
IBM
|
+$266M |
| 4 |
Qualcomm
QCOM
|
+$257M |
| 5 |
Mondelez International
MDLZ
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$356M |
| 2 |
PayPal
PYPL
|
+$290M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$261M |
| 4 |
NVIDIA
NVDA
|
+$248M |
| 5 |
AABA
Altaba Inc
AABA
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.31% |
| 2 | Healthcare | 10.66% |
| 3 | Consumer Discretionary | 10.29% |
| 4 | Communication Services | 8.78% |
| 5 | Financials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
PUT
General Dynamics
GD
$104B
| $24.4M | 0.04% |
118,500
| – | – |
|
|
CSII
527
DELISTED
Cardiovascular Systems, Inc.
CSII
| $24.3M | 0.04% |
862,258
-31,758
| -4% | -$966K |
|
|
SGMO
528
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $24.1M | 0.04% |
1,604,555
+487,033
| +44% | +$5.38M |
|
529
GSK
GSK
$104B
| $24M | 0.04% |
473,646
+356,753
| +305% | +$18.1M |
|
530
SPX Corp
SPXC
$10.1B
| $24M | 0.04% |
816,978
-39,592
| -5% | -$1.04M |
|
531
PUT
Northrop Grumman
NOC
$78.1B
| $23.9M | 0.04% |
83,100
+33,100
| +66% | +$8.91M |
|
|
CA
532
DELISTED
CA, Inc.
CA
| $23.8M | 0.04% |
713,747
-9,745
| -1% | -$322K |
|
533
CALL
Humana
HUM
$46.4B
| $23.8M | 0.04% |
97,700
| – | – |
|
534
Invesco Emerging Markets Sovereign Debt ETF
PCY
$1.29B
| $23.8M | 0.04% |
799,000
+101,000
| +14% | +$2.99M |
|
535
BWX Technologies
BWXT
$13.7B
| $23.7M | 0.04% |
422,283
-217,797
| -34% | -$11.6M |
|
536
CALL
Procter & Gamble
PG
$340B
| $23.6M | 0.04% |
259,600
+23,000
| +10% | +$2.09M |
|
|
AXE
537
DELISTED
Anixter International Inc
AXE
| $23.5M | 0.04% |
276,184
+14,259
| +5% | +$1.1M |
|
538
AerCap
AER
$23.3B
| $23.4M | 0.04% |
458,767
+63,167
| +16% | +$3.1M |
|
539
CALL
LendingTree
TREE
$434M
| $23.3M | 0.04% |
95,300
+40,000
| +72% | +$8.63M |
|
540
Intuitive Surgical
ISRG
$132B
| $23.3M | 0.04% |
200,286
+136,656
| +215% | +$14.9M |
|
541
Bunge Global
BG
$21.1B
| $23.2M | 0.04% |
333,376
+50,223
| +18% | +$3.8M |
|
542
Liberty Media Series C
FWONK
$26.8B
| $23.1M | 0.04% |
628,322
-5,593,072
| -90% | -$196M |
|
|
FLOW
543
DELISTED
SPX FLOW, Inc.
FLOW
| $23M | 0.04% |
595,726
+33,638
| +6% | +$1.19M |
|
|
EXPR
544
DELISTED
Express, Inc.
EXPR
| $23M | 0.04% |
169,833
+26,748
| +19% | +$3.38M |
|
545
CALL
UnitedHealth
UNH
$358B
| $22.9M | 0.04% |
117,000
-7,300
| -6% | -$1.41M |
|
546
Sabre
SABR
$900M
| $22.9M | 0.04% |
1,265,283
-577,668
| -31% | -$11.2M |
|
|
NLSN
547
DELISTED
Nielsen Holdings plc
NLSN
| $22.9M | 0.04% |
552,364
-874,573
| -61% | -$34.9M |
|
|
AGN
548
CALL
DELISTED
Allergan plc
AGN
| $22.8M | 0.04% |
111,200
-90,000
| -45% | -$20.9M |
|
|
CTLT
549
DELISTED
CATALENT, INC.
CTLT
| $22.7M | 0.03% |
569,737
+243,432
| +75% | +$9.02M |
|
550
General Motors
GM
$76.3B
| $22.7M | 0.03% |
562,182
-4,105
| -0.7% | -$150K |
|
Similar funds
David Shaw's Q3 2017 Portfolio in Review
As of Q3 2017, David Shaw held 3,794 positions worth $65.1B, up 7.7% from $60.5B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.
David Shaw's Q3 2017 filing shows 469 new, 1,367 increased, 1,237 reduced and 370 closed positions. Its largest new stake was Baker Hughes: 3,076,914 shares worth $113M. The largest sale was Gilead Sciences, an estimated $356M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- David Shaw's largest Q3 2017 buy was Baker Hughes: 3,076,914 shares worth $113M.
- David Shaw added most to Comcast in Q3 2017, an estimated $354M increase.
- David Shaw's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $356M.
- David Shaw fully exited Mobileye N.V. in Q3 2017, selling an estimated $72.4M.
- David Shaw's ten largest holdings make up 9.6% of its $65.1B portfolio in Q3 2017.
- David Shaw opened 469 new positions and closed 370 in Q3 2017.
- David Shaw's portfolio value rose 7.7% quarter-over-quarter to $65.1B.
Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.